Big drugmakers must face US overcharge claims on medications for low-income patients

A U.S. appeals court revived a whistleblower lawsuit accusing four large drugmakers of overcharging federal and state governments by 'hundreds of millions' of dollars for medications for low-income and uninsured patients. The decision reopens material legal and reputational risk and could exert multi-percent downside pressure on the implicated companies as potential damages and regulatory scrutiny are revisited.

Analysis

A U.S. appeals court revived a whistleblower lawsuit accusing four large drugmakers of overcharging federal and state governments by 'hundreds of millions' of dollars for medications for low-income and uninsured patients. The decision reopens material legal and reputational risk and could exert multi-percent downside pressure on the implicated companies as potential damages and regulatory scrutiny are revisited.